# A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

> **NCT05970978** · PHASE2 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 152 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** regular treatment
- **DRUG:** Intensive treatment

## Key facts

- **NCT ID:** NCT05970978
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-28
- **Primary completion:** 2024-07-19
- **Final completion:** 2025-01-26
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970978, "A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05970978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*